New analysis incorporates real world insights from industry leaders
17 April 2014
Today the Pharmaceutical Research and Manufacturers of America (PhRMA) released a report that outlines two potential growth trajectories for the U.S. biopharmaceutical sector and the top policy factors that enable the industry to innovate and, in turn, contribute to the U.S. economy.
PhRMA Report Reveals Growth Trajectories and Policy Factors Affecting Biopharmaceutical Growth
17 April 2014
The Pharmaceutical Research and Manufacturers of America (PhRMA) released a report that outlines two potential growth trajectories for the US biopharmaceutical sector. Developed by the Battelle Technology Partnership Practice, the report finds that coverage and payment policies, a science-based regulatory system, and strong intellectual property (IP) protections drive US leadership in biopharmaceutical innovation, and if negative trends in these key policy areas continue, jobs supported by the industry would decrease over the next decade.
Experts offered a transfer to the federal level funding therapy ten rare diseases
17 April 2014
Russian experts are going to appeal to the government proposal to transfer funding to the federal level of the ten most expensive rare diseases included in the list of 24 life-threatening and rare chronic progressive diseases that can shorten life expectancy of a citizen or disability. This message on April 3 , Deputy Director General of the Institute of EurAsEC Elena Krasil'nikova during the "round table" dedicated treatment of rare diseases.
Microsoft backs Russian-based research into Alzheimer’s
17 April 2014
Russian scientists from Novosibirsk and Moscow have received a grant from Microsoft for the use of its Windows Azure cloud platform in their research into the human genes responsible for the Alzheimer’s disease. They can use the platform for 12 months, Microsoft announced.
New Ryazan factory to make nanobased drugs
17 April 2014
OOO Fort, a Russian company, is launching a new pharmaceutical facility outside the city of Ryazan in Central Russia later this week, the Uzrf.ru portal for Russian healthcare institutions reported .
Patient-centric Engagement and the Digital Age
09 April 2014
The Internet and various services using it as a platform evolve at such a rapid pace that it is difficult to keep track of everything and to understand its significance to clinical trials. One of the key aspects to consider is access to the Internet. In 1995, there were 16 million Internet users or 0.4% of the world’s population. In just 17 years, this figure has grown to 2.4 billion and 34.3% adoption. At the current rate, each year, the penetration percentage sees a 2-4% growth.
Biotech's breathless quarter of IPOs brings in $2.1B for R&D
09 April 2014
Back in January, at the annual J.P. Morgan Healthcare Conference, across hotel lobbies and crowded hallways and standing-room-only cafes, one could hardly escape talk about the biotech IPO boom. More than 45 life sciences companies had made their way onto the public markets in the preceding year, banking more than $3 billion in the process, and many at the industry's annual sewing circle believed biotech was about to see its shadow on Wall Street. Furthermore, rumor had it at least 25 upstarts were already embarking on road shows and wooing underwriters, all looking to squeeze out of a shrinking window before it snapped shut and burst the biotech bubble in the process.
Biopharmaceuticals Approval Trends in 2013
09 April 2014
In 2013, 19 products containing new biopharmaceutical molecular entities were approved in the United States and/or the European Union. Approval numbers for 2013 are above average as compared to the previous five years, which recorded a mean approval rate of 13 products. This annual approval rate was surpassed only in 2009, a year in which 20 new products came on the market.
Russia’s first commercial early-stage clinical trial center launched in St. Pete
09 April 2014
Russia’s first commercial R&D center for early-stage clinical trials opened in St. Petersburg last week as a joint project between the state-owned RVC Biofund and its portfolio company, BioEc, the RVC website announced .
New atherosclerosis therapy nears in vitro test phase in Siberia
09 April 2014
Scientists at Tomsk Polytechnic University and the local Research Institute of Cardiology are developing a new method of treating atherosclerosis using a coronary stent with a biodegradable coating, reported the website of Vesti-Tomsk, a regional TV and radio broadcasting company.
Merry Christmas and Happy New Year!
28 December 2024
NovaMedica team in the TOP 100 INFLUENTIAL PEOPLE IN THE PHARMACEUTICAL BUSINESS 2024
28 November 2024
05 November 2024
2024 drug approvals: Small companies loom large with several key FDA nods
13 January 2025
Special Regulations for Foreign-Packaged Medicines Extended Until the End of 2025
13 January 2025
Russia Begins Production of Terbium-161 Isotope for Cancer Therapy
10 January 2025
FMBA has begun clinical trials of a vaccine against five serotypes of meningococcus
10 January 2025